The Leading Industry Event Driving Next-Generation Psychosis R&D
Uniting Biotech & Pharma Leaders Transforming Psychosis Drug Development
2025 is set to be a pivotal year for psychosis drug development, with a surge in clinical advancements and growing momentum from key collaborations since 2024. There has never been a better time for a dedicated forum for the R&D scientists paving the way in novel psychosis drug discovery and development.
Uniquely positioned to address the hurdles in translational validity, patient heterogeneity, placebo effect and scaling trials, don’t miss this brand-new opportunity to join the inaugural Innovation in Psychosis Therapeutics Summit and collaborate with 60+ leading experts across discovery, preclinical, translational and clinical development.
With the rising unmet need to address the burden of psychosis and the significant side effects associated with atypical antipsychotics, now is the moment to build on Cobenfy’s breakthrough success and collaboratively drive the development of next generation approaches for targeting psychosis across the disease spectrum.
World-Class Speaker Faculty:
Other Events in the Series
